Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
Abstract Background The homologous recombination deficiency (HRD) test is an important tool for identifying patients with epithelial ovarian cancer (EOC) benefit from the treatment with poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi). Using whole exome sequencing (WES)-based platform...
Saved in:
Main Authors: | Ying-Cheng Chiang, Hsien-Neng Huang, Kuan-Ting Kuo, Wuh-Liang Hwu, Po-Han Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13048-024-01565-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01) -
CT-based radiomics predicts HRD score and HRD status in patients with ovarian cancer
by: Yujiao Wu, et al.
Published: (2025-01-01) -
Homologous recombination deficiency test validation in patients with high-grade advanced ovarian cancer
by: Angelica Nogueira Rodrigues, et al.
Published: (2025-02-01) -
Competence induction of homologous recombination genes protects pneumococcal cells from genotoxic stress
by: David De Lemos, et al.
Published: (2025-01-01) -
De novo assembly of the mitochondrial genome of Glycyrrhiza glabra and identification of two types of homologous recombination configurations caused by repeat sequences
by: Guowang Zhou, et al.
Published: (2025-01-01)